Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9324501 | 0.81 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL29948771 | 0.77 | ALDH1A1 (0.55) | ALDH1A1TSHRKDM6BKDM5CEGLN1 | |
| SCHEMBL17731042 | 0.77 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL8786935 | 0.69 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM6BKDM5CEGLN1 | |
| SCHEMBL8778249 | 0.69 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM6BKDM5CEGLN1 | |
| SCHEMBL291621 | 0.68 | — | — | |
| SCHEMBL1324058 | 0.67 | — | — | |
| SCHEMBL17686889 | 0.66 | ALDH1A1 (0.52) | ALDH1A1TSHRKDM6BKDM5CEGLN1 | |
| Hydrochloric Acid SCHEMBL519616 | 0.66 | KDM6B (0.60) | ALDH1A1TSHRKDM6BKDM5CEGLN1 | |
| SCHEMBL28937863 | 0.66 | ALDH1A1 (0.52) | ALDH1A1TSHRKDM6BKDM5CEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0438314-B1 | Process for the production of 3-(1-amino-1,3-dicarboxy-3-hydroxy-but-4-yl) indole | TECHNOLOGY FINANCE CORP (ZA) | 1994-04-27 | — | — | EP | claimed |
| US-5128482-A | Process for the production of 3-1(1-amino-1,3-dicarboxy-3-hydroxy-but-4-yl) indole | TECHNOLOGY FINANCE CORPORATION (PROPRIETARY) LIMITED (ZA) | 1992-07-07 | — | — | US | claimed |
| EP-0438314-A1 | Process for the production of 3-(1-amino-1,3-dicarboxy-3-hydroxy-but-4-yl) indole | TECHNOLOGY FINANCE CORPORATION (PROPRIETARY) LIMITED (ZA) | 1991-07-24 | — | — | EP | claimed |
| EP-2384327-A1 | FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960383-B2 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL SA (ES) | 2011-06-14 | — | — | US | disclosed |
| EP-1758869-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL SA (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | ALMIRALL PRODESFARMA, SA (ES) | 2008-11-13 | — | — | US | disclosed |
| EP-1758869-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123692-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
| US-5434175-A | PARASITICIDES, INSECTICIDES AND MITICIDES | ROUSSEL UCLAF (FR) | 1995-07-18 | — | — | US | disclosed |
| EP-0438314-B1 | Process for the production of 3-(1-amino-1,3-dicarboxy-3-hydroxy-but-4-yl) indole | TECHNOLOGY FINANCE CORP (ZA) | 1994-04-27 | — | — | EP | disclosed |
| US-5128482-A | Process for the production of 3-1(1-amino-1,3-dicarboxy-3-hydroxy-but-4-yl) indole | TECHNOLOGY FINANCE CORPORATION (PROPRIETARY) LIMITED (ZA) | 1992-07-07 | — | — | US | disclosed |
| EP-0438314-A1 | Process for the production of 3-(1-amino-1,3-dicarboxy-3-hydroxy-but-4-yl) indole | TECHNOLOGY FINANCE CORPORATION (PROPRIETARY) LIMITED (ZA) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | PDE12, PDE4A, PDE4B | ALDH1A1 457/4885TSHR 2798/4885KDM6B 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.